Last reviewed · How we verify
Acular LS
Acular LS is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis in the eye.
Acular LS is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis in the eye. Used for Ocular inflammation and pain following cataract surgery, Allergic conjunctivitis, Corneal abrasion pain.
At a glance
| Generic name | Acular LS |
|---|---|
| Also known as | KETOROLAC TROMETHAMINE 0.5% SOLUTION - OPHTHALMIC |
| Sponsor | University of Colorado, Denver |
| Drug class | Topical NSAID |
| Target | COX-1, COX-2 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
By blocking COX-1 and COX-2 enzymes, ketorolac tromethamine reduces prostaglandin-mediated inflammation, pain, and ocular surface irritation. The LS (Low Strength) formulation delivers a reduced concentration of the active ingredient for use in ophthalmic conditions where anti-inflammatory and analgesic effects are desired with a lower systemic exposure profile.
Approved indications
- Ocular inflammation and pain following cataract surgery
- Allergic conjunctivitis
- Corneal abrasion pain
Common side effects
- Ocular irritation or stinging
- Conjunctival hyperemia
- Headache
- Corneal erosion or ulceration (rare)
Key clinical trials
- Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma (PHASE2)
- The Laser in Pseudoexfoliation (LIP) Study (PHASE4)
- Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT (PHASE4)
- S.L. Spray Solution® and Difflam® and Acular®Spray for the Prevention of Postoperative Sore Throat (PHASE4)
- Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity (PHASE4)
- Efficacy of Block Injection of an Anti Inflammatory Medicine in Patients With Mandibular Dental Pain (PHASE2)
- Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
- Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acular LS CI brief — competitive landscape report
- Acular LS updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI